Merck's KEYTRUDA® (pembrolizumab) Demonstrates Improved Overall Survival as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at Final Analysis of Pivotal Phase 3 KEYNOTE-048 Trial - Argus Press
Merck's KEYTRUDA® (pembrolizumab) Demonstrates Improved Overall Survival as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at Final Analysis of Pivotal Phase 3 KEYNOTE-048 Trial Argus Press
KENILWORTH, N.J.--(BUSINESS WIRE)--May 31, 2019--. Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the ...
Comments
Post a Comment